PPT-OBV/PTV/r DSV RBV OBV/PTV/r

Author : ellena-manuel | Published Date : 2018-02-19

DSV placebo Randomisation Partial blind 1870 years Chronic HCV infection Genotype 1 Treatmentnaïve HCV RNA gt 10000 IUml No cirrhosis No HBV or HIV coinfection

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "OBV/PTV/r DSV RBV OBV/PTV/r" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

OBV/PTV/r DSV RBV OBV/PTV/r: Transcript


DSV placebo Randomisation Partial blind 1870 years Chronic HCV infection Genotype 1 Treatmentnaïve HCV RNA gt 10000 IUml No cirrhosis No HBV or HIV coinfection Randomisation 12 if genotype 1a PEARLIV . PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV . + RBV. 2-steps. Randomisation*. Open-label. W12. W8. W24. 18-70 years. Chronic HCV infection . Genotype 1. HCV RNA ≥ 50,000 IU/ml. Treatment-naïve . HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAILAND. When to Treat HCV. . HCV Direct-Acting . Antivirals. (. DAAs. ) in . development. . OVERVIEW. Know your epidemic: what matters. *. 1:1. Open-label. ≥ 18 years. HCV genotype 4. HCV RNA ≥ 1 000 IU/mL. Naïve or pre-treated with PEG-IFN + RBV Compensated cirrhosis ** . No HBV or HIV co-infection. N = 59. W12. OPV/PTV/r + RBV. OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IFN + RBV. Randomisation. Open-label. 18-65 years. HCV genotype 1. HCV RNA > 10,000 IU/ml. Naïve (MALACHITE-I). Failure to . prior PEG-IFN + RBV. (MALACHITE-II). Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . Study. : . o. mbitasvir/paritaprevir/ritonavir. . + . d. asabuvir. . + . ribavirin. . for genotype 1. Treatment regimens. Co-formulated . ombitasvir. N = 100. W12. W24. Arm B: . compensated cirrhosis. N = 31. N = 29. Arm C:. compensated cirrhosis. Arm A: . No cirrhosis. AGATE-II Study: OBV/PTV/r + RBV in genotype 4 Egyptian patients without or with cirrhosis . OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open label. 18-70 years. Chronic HCV infection. Genotype 4 . Treatment-naïve or failure . t. o PEG-IFN + RBV. HCV RNA > 10,000 IU/ml. No cirrhosis**. No HBV or HIV co-infection. N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . Randomisation*. Open-label. >. 18 years. HCV genotype 1. HCV RNA ≥ 10,000 IU. /ml. Treatment naïve and . compensated cirrhosis (Child-Pugh A). or. Null responders to previous PEG-IFN + RBV, with or without cirrhosis. SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . . PEG alfa-. 2a . versus. INF RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . . RBV . versus. . PEG . IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: .

Download Document

Here is the link to download the presentation.
"OBV/PTV/r DSV RBV OBV/PTV/r"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents